Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus UCEPHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus UCEPHAN.
COR-OTICIN vs UCEPHAN
Head-to-head clinical comparison of therapeutic indices and safety profiles.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
UCEPHAN (eculizumab) is a monoclonal antibody that binds to complement protein C5, inhibiting its cleavage to C5a and C5b, thereby preventing the formation of the membrane attack complex (MAC) and terminal complement-mediated cell lysis.
Treatment of steroid-responsive inflammatory conditions of the external ear canal complicated by bacterial infection caused by neomycin- and polymyxin B-susceptible organismsOff-label: short-term treatment of acute otitis externa
Paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysisAtypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathyGeneralized myasthenia gravis (gMG) in anti-acetylcholine receptor (AChR) antibody-positive patientsNeuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody-positive patients
1-2 drops in each affected ear twice daily for 7 days.
500 mg orally every 12 hours or 250 mg orally every 8 hours.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life is 2.1 ± 0.5 hours in adults with normal renal function; prolonged to 20–50 hours in severe renal impairment (CrCl <10 mL/min).
Hydrocortisone is primarily metabolized in the liver via reduction, conjugation (glucuronidation and sulfation), and CYP3A4-mediated oxidation. Neomycin is minimally metabolized and is excreted largely unchanged. Polymyxin B is not significantly metabolized; elimination mainly via renal tubular secretion.
Eculizumab is a monoclonal antibody; it is catabolized via general protein degradation pathways, primarily by the reticuloendothelial system. No specific CYP450 enzyme involvement.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Approximately 70–80% of an administered dose is eliminated unchanged in urine via glomerular filtration and tubular secretion; the remainder (20–30%) is eliminated via biliary/fecal routes, with <5% as metabolites.
70-80% primarily to albumin
Approximately 30% bound to serum albumin.
0.3-0.5 L/kg; distributes into total body water
0.2–0.3 L/kg in adults; distributes primarily into extracellular fluid, with limited penetration into cerebrospinal fluid (only when meninges inflamed).
Oral: 70-80% (first-pass effect minimal); Intramuscular: approximately 90%
Oral: 20–40% (variable due to first-pass metabolism and food effect). Intramuscular: approximately 90%.
No adjustment required.
GFR >50 mL/min: no adjustment; GFR 30-50: 250 mg every 12 hours; GFR 10-29: 250 mg every 24 hours; GFR <10 (not on dialysis): 250 mg every 48 hours.
No adjustment required.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg every 12 hours; Child-Pugh C: 250 mg every 24 hours.
1 drop in each affected ear twice daily for 7 days.
5 mg/kg orally every 12 hours (max 500 mg/dose) for children >1 month.
Same as adult dosing; no specific adjustment required.
Use with caution; consider starting at lower dose (250 mg every 12 hours) and titrating based on renal function.
None.
WARNING: Increased risk of serious or fatal infections due to encapsulated bacteria, including Neisseria meningitidis. Vaccinate patients against meningococcal disease at least 2 weeks prior to administration. Monitor for early signs of infection.
["Prolonged use may result in overgrowth of nonsusceptible organisms including fungi","Ototoxicity: neomycin may cause irreversible cochlear damage if absorbed through the middle ear; avoid use in patients with tympanic membrane perforation","Systemic absorption of hydrocortisone may suppress hypothalamic-pituitary-adrenal (HPA) axis","Sensitization to neomycin may develop with continued use","Avoid prolonged treatment (>10 days) due to increased risk of superinfection"]
["Meningococcal infection risk: Vaccinate and monitor; consider prophylactic antibiotics if urgent treatment needed","Other infections: Increased susceptibility due to complement blockade","Infusion reactions: Discontinue infusion if severe reactions occur","Thrombotic microangiopathy (TMA) complications in aHUS patients following discontinuation"]
["Hypersensitivity to any component","Perforated tympanic membrane (risk of ototoxicity)","Viral or fungal infections of the external ear canal (e.g., herpes simplex, varicella)","Tuberculosis of the ear"]
["Known hypersensitivity to eculizumab or any component of the formulation","Active unresolved Neisseria meningitidis infection","Patients not vaccinated against meningococcal disease unless urgent treatment is required and prophylactic antibiotics are administered"]
Data Pending Review
Data Pending Review
No clinically relevant food interactions.
Avoid alcohol during treatment and for 72 hours after last dose to prevent disulfiram-like reaction. No food restrictions; may be taken with or without food.
First trimester: Limited human data; animal studies show increased risk of cleft palate and neural tube defects at high doses. Second and third trimesters: Associated with intrauterine growth restriction, preterm birth, and neonatal adrenal suppression.
First trimester: No adequate human studies; based on animal data, potential for teratogenicity exists, particularly neural tube defects and cardiac malformations. Second and third trimesters: May cause fetal renal impairment, oligohydramnios, and skull ossification defects with prolonged exposure. Avoid in pregnancy unless benefit outweighs risk.
Present in breast milk; M/P ratio 0.5-0.8 in limited studies. Use caution, especially with high doses or prolonged therapy; monitor infant for growth and adrenal suppression.
Excreted in human milk in low amounts (M/P ratio approximately 0.25). Limited data; caution advised. Monitor infant for rash, diarrhea, or candidiasis.
Increased clearance and volume of distribution in pregnancy may require dose increases; monitor clinical response and adjust accordingly. Avoid abrupt discontinuation; taper slowly.
Increased renal clearance during pregnancy may reduce serum levels; consider therapeutic drug monitoring. No standard dose adjustment established; adjust based on clinical response and serum levels.
Category C
Category C
COR-OTICIN is a fixed-dose combination of hydrocortisone and acetic acid used for otic infections. Hydrocortisone reduces inflammation and itching; acetic acid restores acidic pH to inhibit bacterial/fungal growth. Use only for external ear infections (otitis externa); contraindicated in tympanic membrane perforation to avoid ototoxicity. Shake well before use. Avoid prolonged use (>10 days) to prevent fungal superinfection.
UCEPHAN (cefuroxime) is a second-generation cephalosporin with activity against Haemophilus influenzae and Moraxella catarrhalis. Use with caution in penicillin-allergic patients; cross-reactivity occurs in ~10%. For community-acquired pneumonia, it is an alternative to amoxicillin-clavulanate. In surgical prophylaxis, give 1.5 g IV within 60 minutes before incision. Monitor renal function in elderly or those on aminoglycosides.
Instill 3-5 drops into the affected ear(s) 3-4 times daily for up to 10 days.Lie on side with affected ear up for 5 minutes after instillation.Do not touch dropper tip to ear or surfaces.Do not use if you have a perforated eardrum (history of ear surgery, ear tube, or ear pain with drainage).Discontinue and contact doctor if symptoms worsen or persist after 7 days.
Take exactly as prescribed; finish the full course even if you feel better.If you are allergic to penicillin, tell your doctor before taking this medicine.Common side effects include diarrhea, nausea, and rash; notify your doctor if severe or if you have bloody stools.Do not take with alcohol; may cause disulfiram-like reaction (headache, flushing, vomiting).Store at room temperature, away from moisture and heat.